
News|Videos|November 7, 2023
SunRISe-1: Updated Data With TAR-200 Monotherapy in NMIBC
Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































